2021-2022 Synagis Seasonal Respiratory Syncytial Virus Enrollment Form



Fax Referral To: 1-888-280-1191 OR 787-759-4161 Phone: 1-888-280-1190 OR 787-759-4162 Email Referral To: Customer.ServiceFax@CVSHealth.com Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927

			bmitting a Referra	al			
PATIENT INFORMAT	ION (Complete or include	e demographic :	sheet)				
Patient Name:	DOB: City, State, ZIP Code:						
Address:	City, State, ZIP Code:						
Gender: 🔄 Male 🔛 Femal	e						
Preferred Contact Methods:							
Note: Carrier charges may apply							
rimary Phone: Alternate Phone: Alternate Phone: Minor , Parent/Caregiver/Guardian Name (Last, First):							
Relationship to minor:							
		Last Fou	ur of SSN:	_ Primary Lan	guage:		
2 PRESCRIBER INFOR	MATION						
Prescriber's Name:			State Licens	State License #:			
NPI #: DEA #	: Group or H	Hospital:					
Address: Phone:		City, St	tate, ZIP Code:				
3 INSURANCE INFORM	ATION Please fax copy	of prescription a	and insurance cards w	/ith this form, if	available (front and back)		
Prescription Card:							
Name of Insurer:	ID#:	:	BIN:	PCN:	Group:		
Medical Insurance:							
Subscriber:	ID#:		_ Name of Insurer: _		Phone:		
Secondary Insurance:							
			Name of Insurer: _		Phone:		
4 DIAGNOSIS AND CL	INICAL INFORMATION	ON					
Needs by Date:	Expected date of first i	injection:	Ship to:	Patient 🗌 Of	ffice 🗌 Other:		
Diagnosis (ICD-10):							
Gestational Age: 🗌 < 23 w	/ks (P07.21) 🛛 🗌 23 wks	s (P07.22)	24 wks (P07.23)	🗌 25 w	/ks (P07.24)		
26 wks	s (P07.25) 🗌 27 wks	(P07.26)	28 wks (P07.31)	🗌 29 w	vks (P07.32)		
🗌 30 wk	s (P07.33) 🗌 31 wks	(P07.34)	32 wks (P07.35)	🗌 33 w	/ks (P07.36)		
34 wks	s (P07.37) 🗌 35 wks	s (P07.38)					
Nursing:							
No nursing coordination	Yes, CVS Specialty to	coordinate hon	ne health nurse visit	for injection			
				-			
Chronic Respiratory Dis	-	inatal Period:					
Wilson-Mikity Syndrome			() ()				
=	plasia originating in the per	• •	-				
U Other chronic respiratory	y disease originating in the	e perinatal perio	d (P27.8)				
Concenital Abnormality	of Respiratory System	n.					

enital Abnormality of Respirator

- Congentical Subglottic Stenosis (Q31.1)
- Laryngocele (Q31.3)

- Other Congenital Malformations of Trachea (Q32.1) Other Congenital Malformations of Bronchus (Q32.4)
- Other Congenital Malformations of Larynx (Q31.8)
- Congenital Cystic Lung (Q33.0)

2021-2022 Synagis Seasonal Respiratory Syncytial Virus Enrollment Form

Patient's Gestationa Current Weight:		Patient DOB: Prescriber Phone:						
DIAGNOSIS		Prescriber Phone:						
Patient's Gestationa Current Weight:								
Patient's Gestationa Current Weight:								
Current Weight:	AND CLINICAL INFOR							
Current Weight:		s days Patient's Birth Weight: g / kg	g / lbs (please circle)					
id natient receive 4	g / kg / lbs (please circ	le) Date Recorded://						
	Synagis last season? 🗌 No 🛽	Yes Dates of Synagis doses given this season:						
1ultiple births: 🗌 🏻	No 🗌 Yes Enter names of Sy	nagis candidates (submit separate enrollment forms)	:					
		l-age siblings in home: 🗌 No 🔲 Yes						
NCU history: 🗌 N	o 🗌 Yes 🛛 If yes, NICU name a	and include NICU summary:						
llergies:	gies: Medical conditions not listed below:							
linical Conditions	: 2014 AAP Committee on Infe	ctious Disease and Bronchiolitis Guidelines						
Chronic Lung Disea	ase (CLD):							
< 12 months of a	ge with CLD*							
< 24 months of a	ge with CLD* AND continues t	o require medical support during the 6-month period	before second RSV season					
AND 🗌 Suppler								
🗌 Diuretic	therapy (drugs/dates)	Bronchodilators (drugs/dates)						
CLD of prematurely	defined as gestational age < 31	weeks, 6 days AND requirement for 21% oxygen for at lea	ast the first 28 days after birth					
ongenital Heart D	visease (CHD):							
< 12 months of a	ge at start of season with hemo	odynamically significant CHD such as:						
Acyano ⁻	tic heart disease and receiving	medication to control congestive heart failure and su	rgery to correct					
(meds/date	es)	(surgery date)						
🗌 Modera	te to severe pulmonary hypert	(surgery date) ension						
Other: d	lescribe							
		lantation during the RSV season (date)						
Cyanotic Heart [Disease: diagnosis							
	scular Conditions:							
<pre>< 12 months of a</pre>	ge at start of season and comp	promised handling of secretions AND due to						
Significant abno	ormality of the airway (attach c	linical notes) 🔲 Neuromuscular condition (attach cli	nical notes)					
	GA 28 wks, 6 days AND < 12 mg		,					
	Other medical history (desc							
	ON INFORMATION	,						
MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS					
			Quantity: QS to achieve					
Synagis	50 mg and/or 100 mg vials	Inject 15 mg/kg IM one time per month	15 mg/kg dose					
(palivizumab)		Other:	Refills:					
			Quantity:					
Epinephrine	1:1000 amp	Inject 0.01 mg/kg SC as directed for anaphylaxis	Refills: 0					
Patient is interested in pat	ient support programs	STAMP SIGNATURE NOT ALLOWED Ancillary supplies and	d kits provided as needed for administrati					

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" ATTN: New York and Iowa providers, please submit electronic prescription							
Prescriber's Signature:	Date:	Prescriber's Signature:	Date:				
DAW / May Not Substitute		Substitution Permissible					
"Dispense As Written" / Brand Medically Necessary / Do Not S	ubstitute / No Substitution /	May Substitute / Product Selection Permitted /					

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.